ArticleFrontiers in endocrinology2025
Pharmacological modulation of MRAP2 protein on murine melatonin receptor signaling.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MTNR1A and MTNR1B, crucial for regulating circadian rhythms and various physiological processes, have well- established biological significance. The role of MRAP2, a single transmembrane accessory protein, in modulating the pharmacological activity of melatonin receptors remains unclear. Methods: We first examined the evolutionary profiles of melatonin receptors and MRAP2 by protein sequence alignment and synteny analysis. Bulk RNA-seq was then employed to analyze the expression distribution of these genes. Next, we performed co-immunoprecipitation and Bimolecular Fluorescence Complementation (BiFC) assays to investigate the interaction of MRAP2 with melatonin receptors. We also recruited the GloSensor luminescence assay to assess the impact of MRAP2 on the Gi signaling pathway of melatonin receptors, and conducted fixed-cell ELISA to evaluate MRAP2's effect on melatonin receptor membrane trafficking. Results: Our results revealed that MTNR1A was most conserved in terms of evolution, while all of these genes showed adaptive changes in amphibians and zebrafish likely due to aquatic environment. MRAP2 was found to inhibit the constitutive activity of melatonin receptors and enhance their maximal agonist potency. Additionally, MRAP2 suppressed the membrane trafficking of MTNR1A, but promoted the surface trafficking of MTNR1B. Discussion: These findings highlighted the complex regulatory role of MRAP2, and shed light on its diverse functions in GPCR biology and its potential implications in regulating physiological processes governed by melatonin signaling.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.